ABBV · News · 20260825N
Guidance / Outlook
AbbVie Inc. · 2026-08-25 · Importance 51 · Surprise 60 · In source text
Third-party reporting states that AbbVie raised its full-year 2026 EPS guidance following strong second-quarter 2026 earnings. The report says the updated outlook, together with growth in immunology products, aesthetics, and neuroscience, supported investor confidence in AbbVie’s longer-term strategy. It also notes that competitive pressures and a setback in a key oncology trial remain risks to the outlook.
Key facts
- AbbVie raised its full-year EPS guidance. source
- AbbVie's strong Q2 2026 earnings supported its stock above $265. source
- AbbVie stock is trading above $265. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| net_income | positive | probable | — | AbbVie raised its full-year EPS guidance. |